Most people regain weight over the following weeks and months if they return to previous eating patterns without the medication's appetite-suppressing effects
Injection therapies have the most consistent trial timelines for expected results
Higher risk groups include: People starting GLP-1 medicines for the first time People whose dose is increased too quickly People who eat large, oily, or very sweet meals People with type 2 diabetes using insulin or sulfonylureas People with previous pancreatitis People with gallstones or gallbladder disease People with severe digestive disorders People with gastroparesis People with kidney disease People with dehydration risk People with diabetic retinopathy People with a personal or family history of medullary thyroid carcinoma People with Multiple Endocrine Neoplasia syndrome type 2 People with active mood disorders or suicidal thoughts People planning surgery or procedures under anaesthesia Patients With Diabetes Vs Non-Diabetic Users People with diabetes may use GLP-1 medicines to improve blood sugar control and support weight management
Varady KA, Runchey MC, Reutrakul S, Vidmar AP, Chow LS
New compound reviews, evidence updates, and protocol analysis sourced, cited, and written for people who actually read the studies
